Literature DB >> 31515650

Real-time transfer of lentiviral particles by producer cells using an engineered coculture system.

Lauren M Timmins1, Riya S Patel1, Matthew S Teryek1, Biju Parekkadan2.   

Abstract

Lentiviruses are quite effective gene delivery systems for stable production of genetically engineered human cells. However, prior to using lentivirus to deliver genetic materials to cells of interest, the normal course of production of these lentiviruses involves a lengthy collection, purification, preservation, and quantification process. In this report, we demonstrate the ability for producer HEK293T cells to simultaneously produce lentiviral particles and transduce (i.e., infect) target cells through a membrane-based coculture system in a continuous, real-time mode which negates the need for a separate viral collection and quantification process. The coculture system was evaluated for major design features such as variations in HEK293T seeding density, target cell type densities, as well as membrane porosities to identify key relationships between lentiviral particle production rate and infection kinetics for adherent and suspension cell types. As a proof-of-concept for the creation of an engineered cell immunotherapy, we describe the ability to engineer human T cells isolated from PBMCs under the control of this coculture system in under 6 days with a GFP construct. These studies suggest the capability to combine and more closely automate the transfection/transduction process in order to facilitate well-timed and cost-effective transduction of target cell types. These experiments provide novel insight into the forthcoming transition into improved manufacturing systems for viral production and subsequent cell engineering.

Entities:  

Keywords:  Engineered cell therapy; Lentivirus transduction; Scalable engineering systems

Year:  2019        PMID: 31515650      PMCID: PMC6787137          DOI: 10.1007/s10616-019-00343-0

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  28 in total

1.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  Kinetic analyses of stability of simple and complex retroviral vectors.

Authors:  F Higashikawa; L Chang
Journal:  Virology       Date:  2001-02-01       Impact factor: 3.616

Review 3.  Downstream processing of oncoretroviral and lentiviral gene therapy vectors.

Authors:  María de Las Mercedes Segura; Amine Kamen; Alain Garnier
Journal:  Biotechnol Adv       Date:  2006-01-30       Impact factor: 14.227

Review 4.  Challenges of up-scaling lentivirus production and processing.

Authors:  Alexandra McCarron; Martin Donnelley; Chantelle McIntyre; David Parsons
Journal:  J Biotechnol       Date:  2016-10-18       Impact factor: 3.307

5.  Production, purification and titration of a lentivirus-based vector for gene delivery purposes.

Authors:  Masoud Nasri; Ali Karimi; Mehdi Allahbakhshian Farsani
Journal:  Cytotechnology       Date:  2014-03-06       Impact factor: 2.058

6.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.

Authors:  Carolina Gándara; Valerie Affleck; Elizabeth Ann Stoll
Journal:  Hum Gene Ther Methods       Date:  2018-01-24       Impact factor: 2.396

Review 7.  The inside out of lentiviral vectors.

Authors:  Stéphanie Durand; Andrea Cimarelli
Journal:  Viruses       Date:  2011-02-14       Impact factor: 5.818

8.  Comparison of lentiviral vector titration methods.

Authors:  Martine Geraerts; Sofie Willems; Veerle Baekelandt; Zeger Debyser; Rik Gijsbers
Journal:  BMC Biotechnol       Date:  2006-07-12       Impact factor: 2.563

Review 9.  Gene therapy for PIDs: progress, pitfalls and prospects.

Authors:  Sayandip Mukherjee; Adrian J Thrasher
Journal:  Gene       Date:  2013-04-06       Impact factor: 3.688

10.  Towards routine manufacturing of gene therapy drugs.

Authors:  Otto-Wilhelm Merten; J Fraser Wright
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-13       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.